Cronos Group Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Ryan Gorenstein
- Full Time Employees
- 610
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4491 Concession Road 12 Stayner ON Canada L0M 1S0
- IPO Date
- Feb 27, 2018
- CIK
- 0001656472
- Website
- thecronosgroup.com
- Similar Companies
- Business
- Cronos Group Inc. is a global cannabinoid company focused on building disruptive intellectual property through advancing cannabis research, technology and product development. The company offers a portfolio of cannabis and cannabis-derived products including dried flower, pre-rolls, edibles, vapes, oils, vaporizers, concentrates and tinctures under brands such as Spinach, PEACE NATURALS, Lord Jones and Cove; it targets adult-use recreational markets in Canada and medical markets in Israel through regulated channels like provincial distributors and pharmacies. Founded in 2012 and headquartered in Toronto, Ontario, Canada, Cronos Group operates an asset-light model emphasizing brand development, innovation in rare cannabinoids via biosynthesis partnerships like Ginkgo Bioworks, and geographic diversification across North America, Israel and select international markets. Recent developments include obtaining majority board control of Cronos GrowCo in July 2024 to expand cultivation capacity by 70% with completion targeted for Q2 2025 and initial sales in the second half of the year; providing C$30 million in convertible debt financing to High Tide Inc. in July 2025 to support retail ecosystem growth; and reporting Q3 2025 net revenue of $19.5 million with ongoing focus on margin expansion and flower supply improvements into 2026.
Company News
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Cronos' brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock
Marijuana reform is emerging as a midterm elections issue on both sides of the aisle
Cronos Group: This Cannabis Name Isn't Reliant On U.S. Legalization Efforts
Cronos: Strong Quarter, And The Outlook For The Future Is Positive Thanks To M&A
Cronos Group Inc. (CRON:CA) Q2 2026 Earnings Call Transcript
Cronos Group Q2 Earnings Call Highlights
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
Cronos Group Reports 2026 Second Quarter Results
3 Top Canadian Marijuana Stock Picks To Add Value To Your Portfolio
Cyprus: TotalEnergies Approves the Development of the Cronos Gas Field to Supply Europe with LNG
Cronos' SOURZ by Spinach® Expands its Lineup of Edibles
Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026
3 Canadian Marijuana Stocks For Better Investing And Trading 2026
Top Canadian Marijuana Stock Picks For Investors Today
Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?
Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders